PRO-THYMUS: a groundbreaking solution to restore the immune system in AML patients, laureate of the Eurostars 3 program

Two Small and medium-sized enterprises (SMEs) and two world-leading institutes from Netherlands and France join forces to propose PRO-THYMUS, a novel groundbreaking solution combining cell and gene therapy to swiftly restore the immune system in patients with acute myeloid leukemia (AML) after blood (hematopoietic) stem cell transplantation (HSCT).

Led by Genewity B.V. (NL), reuniting Institut Imagine (Inserm, AP-HP, Université Paris Cité, FR), Smart Immune (FR) and Leiden University Medical Center (LUMC, NL), the PRO-THYMUS project is laureate of the third EUROSTARS program, which aims to support research and development performing SMEs, fostering their international collaboration capacities.

Please find the full press release below.